Taiwan Bio-Manufacturing Corp (TBMC, 臺灣生物醫藥製造), a government-initiated biotech company, on Friday staged its first public event in Taipei, during which it outlined its business model as being similar to that of contract chipmaker Taiwan Semiconductor Manufacturing Co (TSMC, 台積電) and highlighted its strategic alliance with a US technology-focused biomanufacturing company.
The company, co-established by the Industrial Technology Research Institute (ITRI) and the Development Center for Biotechnology (DCB) last year, on Friday announced a strategic alliance with National Resilience Inc from the US, which it said would give it access to the latter’s expertise in biologics, vaccines, nucleic acids, cell therapy and gene therapy.
TBMC was started following the government’s realization during COVID-19 that Taiwan needed to have its own pharmaceutical manufacturing capabilities, Minister of National Development Kung Ming-hsin (龔明鑫) told a news conference in Taipei.
Photo courtesy of Taiwan Bio-Manufacturing Corp
“It is both a health issue and a national security issue,” he said.
The pandemic put Taiwan’s inability to mass produce mRNA vaccines under the spotlight, TBMC chairman and acting CEO Michel Chu (瞿志豪) said.
“Then-vice president Chen Chien-jen (陳建仁) and then-vice premier Shen Jong-chin (沈榮津) initiated a plan to start a company that specializes in the contract manufacturing of biologics, but can also manufacture vaccines during a pandemic,” Chu said in a video played at the news conference that introduced the company.
Chu also told the audience that the company plans to make the most of Taiwan’s advantages — abundant biotech talent and an outstanding smart manufacturing industry — to catapult the country into becoming a global market for contract development and manufacturing organizations (CDMOs).
CDMOs are companies that provide pharmaceutical companies with outsourcing options for drug development and manufacturing to lower risks and capital investment in advanced manufacturing processes.
TBMC is thus not only similar to TSMC in name, but also in its strategy of specializing in advanced contract manufacturing, Chu said.
The establishment of TBMC is based on the “successful experience” of TSMC, he added.
TBMC, like TSMC in 1986, was partly funded by the government, first employed talent from the ITRI — and also the DCB in the case of TBMC — and used foreign technologies and innovations “to secure the trust of future clients,” Chu said.
TSMC’s foreign partner back then was Royal Philips Electronics NV — which transferred some of its semiconductor patents to TSMC — while TBMC works with National Resilience.
“There are very few CDMOs in the world that out-license,” Chu said. “Many companies around the world would love for TSMC to authorize its advanced manufacturing technologies to them, but TSMC would definitely not be willing to do so.”
The reason TBMC was able to strike a deal with National Resilience was not just its special Taiwan connection — Resilience vice chairman Patrick Yang (楊育民) is Taiwanese American — but also because Taiwan has the exceptional automated and smart manufacturing capabilities that large-molecule drugs increasingly require, Chu said.
Large-molecule drugs, also known as biologics, are made from living organisms, while small-molecule drugs, which make up most of the pharmaceutical drugs on the market, are chemically synthesized.
Minister of Economic Affairs Wang Mei-hua (王美花) added that Taiwan has an edge when comes to talent, its medical system and protection of intellectual property, but “as the pharmaceutical industry is a field where big companies gain the most by remaining large, international collaboration is crucial for Taiwan’s biotech industry.”
CDMO shows great potential for biologics in Asia, Wang said, adding that TBMC has established a lab in the Taipei Bioinnovation Park and that it aims to have a Good Manufacturing Practices-grade factory in the Hsinchu Biomedical Science Park within two years.
“We’re hoping TBMC will become another ‘sacred mountain that protects the nation’ [as TSMC is referred to among Taiwanese] in the decades to come,” the minister said.
Elon Musk’s lieutenants have reached out to chip industry suppliers, including Applied Materials Inc, Tokyo Electron Ltd and Lam Research Corp, for his envisioned Terafab, early steps in an audacious and likely arduous attempt to break into the production of cutting-edge chips. Staff working for the joint venture between Tesla Inc and Space Exploration Technologies Corp (SpaceX) have sought price quotes and delivery times for an array of chipmaking gear, people familiar with the matter said. In past weeks, they’ve contacted makers of photomasks, substrates, etchers, depositors, cleaning devices, testers and other tools, according to the people, who asked not to
Taiwan is attracting a growing number of foreign jobseekers as companies increasingly recruit overseas talent to ease labor shortages and expand global reach, recruitment platform 104 Job Bank (104人力銀行) said yesterday. More than 40,000 foreign nationals searched for jobs in Taiwan through the platform last year, a 28 percent increase from a year earlier, the company said. Malaysians accounted for the largest share of overseas jobseekers at 12.2 percent, followed by Indonesians at 11.9 percent and Vietnamese at 10.8 percent. Indonesian applicants surged more than 50 percent year-on-year, while Vietnamese jobseekers rose by more than 30 percent. Applicants from the
NO SHORTCUTS: Asked about Elon Musk’s Terafab initiative, TSMC CEO C.C. Wei said it takes two to three years to build a fab and another one to two to ramp it up Taiwan Semiconductor Manufacturing Co (TSMC, 台積電) yesterday raised its revenue growth forecast for this year to above 30 percent, up from the 25 percent it estimated three months earlier, citing extremely robust artificial intelligence (AI)-related chip demand. “Our customers and customers’ customers, who are mainly cloud service providers, continue to send us very positive signals and outlook,” TSMC chairman and CEO C.C. Wei (魏哲家) said at an earnings conference. The company also hiked its capital expenditure for this year toward the higher end of its forecast, or US$56 billion, as it aims to step up advanced chip capacity expansions, such as
The founder of Chinese property giant Evergrande Group (恆大集團) has pleaded guilty to charges of fraud and bribery, a court said yesterday, the latest blow for what was once the country’s leading developer. Evergrande’s rise was propelled by decades of rapid urbanization and rising living standards, but in 2020, its access to credit dramatically narrowed when the government introduced curbs on excessive borrowing and speculation. The company defaulted in 2021 after struggling to repay creditors. Founder Xu Jiayin (許家印), 67, known as Hui Ka Yan in Cantonese, was reportedly held by police in 2023, with Evergrande saying he had been subjected to
RSS